JP7022136B2 - 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物 - Google Patents

非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物 Download PDF

Info

Publication number
JP7022136B2
JP7022136B2 JP2019538108A JP2019538108A JP7022136B2 JP 7022136 B2 JP7022136 B2 JP 7022136B2 JP 2019538108 A JP2019538108 A JP 2019538108A JP 2019538108 A JP2019538108 A JP 2019538108A JP 7022136 B2 JP7022136 B2 JP 7022136B2
Authority
JP
Japan
Prior art keywords
ubenimex
administered
nash
inhibitors
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019538108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529566A5 (enExample
JP2019529566A (ja
Inventor
シャオフェン・シオン
デイビッド・エイ・コリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiger Biopharmaceuticals Inc
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of JP2019529566A publication Critical patent/JP2019529566A/ja
Publication of JP2019529566A5 publication Critical patent/JP2019529566A5/ja
Application granted granted Critical
Publication of JP7022136B2 publication Critical patent/JP7022136B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019538108A 2016-09-28 2017-09-28 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物 Expired - Fee Related JP7022136B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662400963P 2016-09-28 2016-09-28
US62/400,963 2016-09-28
US201762460606P 2017-02-17 2017-02-17
US62/460,606 2017-02-17
US201762469722P 2017-03-10 2017-03-10
US62/469,722 2017-03-10
PCT/US2017/054087 WO2018064373A1 (en) 2016-09-28 2017-09-28 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Publications (3)

Publication Number Publication Date
JP2019529566A JP2019529566A (ja) 2019-10-17
JP2019529566A5 JP2019529566A5 (enExample) 2020-07-02
JP7022136B2 true JP7022136B2 (ja) 2022-02-17

Family

ID=61760848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538108A Expired - Fee Related JP7022136B2 (ja) 2016-09-28 2017-09-28 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物

Country Status (6)

Country Link
US (2) US10588880B2 (enExample)
EP (1) EP3518918A4 (enExample)
JP (1) JP7022136B2 (enExample)
KR (1) KR102399254B1 (enExample)
CN (1) CN109862888B (enExample)
WO (1) WO2018064373A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
CA3082178A1 (en) * 2017-11-28 2019-06-06 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
JP2021522247A (ja) * 2018-04-24 2021-08-30 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 肝疾患における好中球エラスターゼ阻害薬の使用
EP3811937A1 (en) * 2019-10-24 2021-04-28 Sorbonne Universite Compounds for use in the prevention and/or treatment of non-alcoholic fatty liver disease
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009109426A (ja) 2007-10-31 2009-05-21 Sysmex Corp 検体前処理液、ウイルス測定用キット及びウイルス検出方法
JP2016505613A (ja) 2013-01-03 2016-02-25 オラムド エルティーディー． Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052449A (en) 1974-07-01 1977-10-04 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
US4029547A (en) 1974-07-01 1977-06-14 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
JPH0759507B2 (ja) * 1989-02-23 1995-06-28 日本化薬株式会社 骨髄異形成症候群治療剤
CN1098249C (zh) * 1995-06-21 2003-01-08 国家医药管理局四川抗菌素工业研究所 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
US9072732B2 (en) 2010-11-22 2015-07-07 The Regents Of The University Of California Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
EP2827849A4 (en) 2012-03-23 2015-11-18 Univ Leland Stanford Junior TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
PT3043865T (pt) * 2013-09-11 2021-01-14 Univ Claude Bernard Lyon Métodos e composições farmacêuticas para o tratamento da infeção por vírus da hepatite b
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
PL3077047T3 (pl) * 2013-12-04 2019-10-31 Galmed Res & Development Ltd Sole aramcholu
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
CN104784178B (zh) * 2015-05-08 2017-04-12 重庆医科大学 尼克酰胺作为有效成分在制备乙型肝炎治疗药物中的用途
CN104887655A (zh) * 2015-06-12 2015-09-09 上海来益生物药物研究开发中心有限责任公司 乌苯美司在制备用于预防和治疗炎症疾病和与炎症相关的感染疾病的药物制剂中的应用
JP2018536710A (ja) 2015-11-06 2018-12-13 ジェンファイア・セラピューティクス・インコーポレイテッドＧｅｍｐｈｉｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 混合型脂質異常症の治療
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
CA3082178A1 (en) 2017-11-28 2019-06-06 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009109426A (ja) 2007-10-31 2009-05-21 Sysmex Corp 検体前処理液、ウイルス測定用キット及びウイルス検出方法
JP2016505613A (ja) 2013-01-03 2016-02-25 オラムド エルティーディー． Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal of Oncology，2016年，Vol.49，pp.89-98

Also Published As

Publication number Publication date
KR102399254B1 (ko) 2022-05-17
EP3518918A4 (en) 2020-04-22
CN109862888B (zh) 2022-08-12
KR20190058532A (ko) 2019-05-29
US20200237696A1 (en) 2020-07-30
EP3518918A1 (en) 2019-08-07
US11571403B2 (en) 2023-02-07
US20190307714A1 (en) 2019-10-10
WO2018064373A1 (en) 2018-04-05
CN109862888A (zh) 2019-06-07
US10588880B2 (en) 2020-03-17
JP2019529566A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
JP7022136B2 (ja) 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物
Gawrieh et al. Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial
AU2013259526B2 (en) New methods
US10441560B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
ES3026786T3 (en) Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease
TW201815420A (zh) 使用fxr促效劑之方法
Kojecky et al. A single or split dose picosulphate/magnesium citrate before colonoscopy: comparison regarding tolerance and efficacy with polyethylene glycol. A randomized trial.
KR102205368B1 (ko) Fxr 작용제의 신규 요법
TW201811372A (zh) 利用fxr促效劑之方法
CN111093705A (zh) 包含fxr激动剂的组合
AU2018375298A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
EP1997485A1 (en) Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis
US20230181601A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
EP4153165A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
JP2022533603A (ja) １５－ＨＥＰＥおよび／または１５－ＨＥＴｒＥを含む組成物、ならびに心血管代謝性疾患、メタボリックシンドローム、および／または関連疾患を治療または予防する方法
Ha et al. Diabetes & Metabolism Journal
TW202214256A (zh) 非酒精性脂肪肝炎（ｎａｓｈ）之治療
HK40089720A (zh) 非酒精性脂肪性肝炎(nash)的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200521

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211216

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211224

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220204

R150 Certificate of patent or registration of utility model

Ref document number: 7022136

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees